Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 7/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072875 | 0.76 | ASAH1 (0.44) | ASAH1 | |
| SCHEMBL2072869 | 0.73 | ASAH1 (0.56) | ASAH1NAMPT | |
| SCHEMBL2071236 | 0.70 | ASAH1 (0.56) | ASAH1NAMPT | |
| SCHEMBL2072379 | 0.69 | NAAA (0.50) | ASAH1NAMPTNAAA | |
| SCHEMBL4658508 | 0.67 | ASAH1 (0.48) | ASAH1 | |
| SCHEMBL6225068 | 0.65 | ASAH1 (0.54) | ASAH1 | |
| SCHEMBL2071214 | 0.64 | ASAH1 (0.57) | ASAH1 | |
| SCHEMBL15537158 | 0.64 | ASAH1 (0.69) | ASAH1 | |
| SCHEMBL20590760 | 0.64 | ASAH1 (0.69) | ASAH1 | |
| SCHEMBL20590755 | 0.64 | ASAH1 (0.78) | ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001878-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE | SANOFI SA (FR) | 2011-10-12 | — | — | EP | disclosed |
| US-7897616-B2 | Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20090076068-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| EP-2001878-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE | sanofi-aventis (FR) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110215-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE | SANOFI-AVENTIS (DE) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076068-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LPL, PLAA | ASAH1 107/4885NAMPT 991/4885NAAA 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.